Latest News

The planned campus at the New Albany International Business Park will use a flexible, modular design combining drug substance and drug product manufacturing with digital and automation technologies.

The NMPA approved VELSIPITY in February 2026 for adults with moderately to severely active ulcerative colitis (UC) who had an inadequate response, lost response or were intolerant to conventional therapy or a biologic agent.

It is now integrating those businesses under Asahi Kasei Therapeutics, the name of its existing Japanese pharmaceutical unit.

The deal gives Kyowa Kirin access to Knight’s pan-American commercial infrastructure while allowing Knight to add a targeted oncology therapy to its portfolio.

Sanofi will pay Regeneron US$1 billion upfront, with development, regulatory, and commercial milestones potentially adding another US$ 7 billion.

Through the partnership, startups will gain opportunities to work with Unilabs on technology integration, proof-of-concept projects, and commercial partnerships.

The Mainz-based biopharmaceutical company said the closures will affect about 1,800 employees at sites in Tübingen, Marburg and Idar-Oberstein.

The financing comes as NorthStar expands its role in the radiopharmaceutical supply chain, particularly for actinium 225 (Ac 225), an alpha-emitting radioisotope used to develop targeted cancer therapies.

Profluent will conduct the computational design work using its Profluent Protein Atlas, a dataset containing more than 115 billion unique protein sequences.